Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal

被引:59
|
作者
Singh, Naveena [1 ]
Gilks, C. Blake [2 ,3 ]
Wilkinson, Nafisa [4 ]
McCluggage, W. Glenn [5 ]
机构
[1] Barts Hlth NHS Trust, Dept Cellular Pathol, London E1 2ES, England
[2] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] St James Hosp, Dept Histopathol, Leeds, W Yorkshire, England
[5] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland
关键词
diagnosis; high-grade serous carcinoma; ovary; primary site; staging; INTRAEPITHELIAL CARCINOMA; FALLOPIAN-TUBE; ORIGIN; CANCER; WOMEN; REPRODUCIBILITY; ADENOCARCINOMA; FREQUENCY; DIAGNOSIS; SUBTYPES;
D O I
10.1111/his.12419
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The revised FIGO 2013 staging for carcinomas of the ovary, fallopian tube and peritoneum has introduced a single system for tumours originating at these sites. The system requires pathologists to assign a primary site (ovary, tube or peritoneum), but does not provide guidance to aid this assignment. This is particularly problematic in cases of advanced-stage (stage II or greater) high-grade serous carcinoma (HGSC), where there is commonly involvement of two or more sites by tumour, and practice among pathologists in determining where a tumour has arisen varies widely. This has significant implications for recording of tumour incidence and mortality, data collection by cancer registries, and entry into clinical trials. We propose guidelines for assigning the primary site of HGSC based on careful macroscopic and histological assessment. The use of these guidelines, in conjunction with the new FIGO staging system, is intended to act as an impetus to promote debate and provide a uniform and consistent approach in assigning primary tumour site which will facilitate comparison of data between centres.
引用
收藏
页码:149 / 154
页数:6
相关论文
共 50 条
  • [21] p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma
    Beirne, James P.
    McArt, Darragh G.
    James, Jacqueline A.
    Salto-Tellez, Manuel
    Maxwell, Perry
    McCluggage, W. Glenn
    [J]. HISTOPATHOLOGY, 2016, 68 (04) : 615 - 618
  • [22] Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
    Jennifer Ducie
    Fanny Dao
    Michael Considine
    Narciso Olvera
    Patricia A. Shaw
    Robert J. Kurman
    Ie-Ming Shih
    Robert A. Soslow
    Leslie Cope
    Douglas A. Levine
    [J]. Nature Communications, 8
  • [23] Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
    Ducie, Jennifer
    Dao, Fanny
    Considine, Michael
    Olvera, Narciso
    Shaw, Patricia A.
    Kurman, Robert J.
    Shih, Ie-Ming
    Soslow, Robert A.
    Cope, Leslie
    Levine, Douglas A.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [24] Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma
    Komiyama, Shinichi
    Nishijima, Yoshihiro
    Kondo, Haruhiro
    Nomura, Hiroyuki
    Yamaguchi, Satoshi
    Futagami, Masayuki
    Arai, Hiroharu
    Yokoyama, Yoshihito
    Suzuki, Nao
    Mikami, Mikio
    Kubushiro, Kaneyuki
    Aoki, Daisuke
    Udagawa, Yasuhiro
    Nishimura, Ryuichiro
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (04) : 657 - 665
  • [25] Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma
    Nik, Niloofar N.
    Vang, Russell
    Shih, Ie-Ming
    Kurman, Robert J.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 : 27 - 45
  • [26] Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor
    Chougule, Abhijit
    Garg, Rashi
    Dey, Pranab
    [J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (01) : 162 - +
  • [27] The prognostic value of the chemotherapy response score in tubo-ovarian or primary peritoneal high-grade serous carcinoma
    Weirich, Larissa
    Bodinaku, Ina
    Bradford, Leslie
    Craig, Wendy
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S231 - S232
  • [28] Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum
    Singh, Naveena
    Gilks, C. Blake
    Wilkinson, Nafisa
    McCluggage, W. Glenn
    [J]. HISTOPATHOLOGY, 2015, 67 (03) : 331 - 337
  • [29] TP53 mutations in serous tubal intraepithelial carcinoma, the putative precursor lesion of ovarian high-grade serous carcinoma
    Kuhn, Elisabetta
    Kurman, Robert J.
    Soslow, Robert A.
    Han, Guangming
    Wang, Tian-Li
    Shih, Le-Ming
    [J]. CANCER RESEARCH, 2011, 71
  • [30] Serous tubal intraepithelial carcinoma (STIC) at the time of primary debulking surgery (PDS) of high-grade serous ovarian cancer (HGSOC): Does it matter?
    Boerner, T.
    Chi, A.
    Zivanovic, O.
    Soslow, R. A.
    Sonoda, Y.
    Gardner, G. J.
    Leitao, M. M., Jr.
    Tew, W. P.
    Konner, J.
    Grisham, R. N.
    O'Cearbhaill, R. E.
    Chi, D. S.
    Abu-Rustum, N. R.
    Roche, K. Long
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 92 - 92